Introduction

This table provides a summary of COVID-19 vaccines that have been assessed and listed for emergency use listing (EUL) by the World Health Organization (WHO). WHO EUL is a risk-based procedure for assessing and listing unlicensed vaccines, with a goal of expediting the availability of vaccine products during public health emergencies, with additional recommendations on their use provided by the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE). This document is intended to support health care providers and public health partners to perform COVID-19 immunization record assessments for vaccines received outside Canada, to counsel patients on recommendations for additional dose(s) of Health Canada authorized vaccines for those with series initiated outside Ontario, and to support standardized data entry in COVaxON. This document is based on WHO Guidance from July 15, 2021 and will be updated, as new products are reviewed and receive EUL by the WHO.

For more information on individuals receiving COVID-19 vaccines outside Ontario see the Ministry of Health’s Guidance for Individuals Vaccinated outside of Ontario/Canada.
Table 1: COVID-19 Vaccines with World Health Organization (WHO) Emergency Use Listing (EUL)*

<table>
<thead>
<tr>
<th>Manufacturer (WHO EUL holder)a</th>
<th>Date Approvedb</th>
<th>Vaccine Generic Name</th>
<th>Vaccine Trade Name(s)**</th>
<th>Vaccine Platform</th>
<th>Doses in Schedule</th>
<th>Interval Between Doses: Authorizedc</th>
<th>Interval Between Doses: Minimumd</th>
<th>COVaxON: Agent Name</th>
<th>COVaxON: Trade Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer – BioNTech</td>
<td>Jan-8-2021</td>
<td>BNT 162b2</td>
<td>Pfizer-BioNTech COVID-19 Vaccine</td>
<td>mRNA</td>
<td>2</td>
<td>21 days</td>
<td>19 days</td>
<td>COVID-19 mRNA</td>
<td>PFIZER-BIONTECH COVID-19 VACCINE mRNA</td>
</tr>
<tr>
<td>Moderna</td>
<td>Jan-25-2021</td>
<td>mRNA-1273</td>
<td>Moderna COVID-19 Vaccine Spikevax</td>
<td>mRNA</td>
<td>2</td>
<td>28 days</td>
<td>21 days</td>
<td>COVID-19 mRNA</td>
<td>MODERNA COVID-19 mRNA-1273</td>
</tr>
<tr>
<td>AstraZeneca/Oxford University</td>
<td>Feb-10-2021</td>
<td>ChAdOx1-S[AZD1222]</td>
<td>AstraZeneca COVID-19 Vaccine Vaxzevria</td>
<td>Viral vector (non-replicating)</td>
<td>2</td>
<td>4 to 12 weeks</td>
<td>28 days</td>
<td>COVID-19 non-replicating vector vaccine</td>
<td>ASTRAZENECA COVID-19 VACCINE</td>
</tr>
<tr>
<td>Serum Institute of India (SII)</td>
<td>Feb-15-2021</td>
<td>ChAdOx1-S[]</td>
<td>COVISHIELD COVID-19 Vaccine COVISHIELD</td>
<td>Viral vector (non-replicating)</td>
<td>2</td>
<td>4 to 12 weeks</td>
<td>28 days</td>
<td>COVID-19 non-replicating vector vaccine</td>
<td>COVID-19 COVISHIELD</td>
</tr>
<tr>
<td>Manufacturer (WHO EUL holder)</td>
<td>Date Approved</td>
<td>Vaccine Generic Name</td>
<td>Vaccine Trade Name(s)**</td>
<td>Vaccine Platform</td>
<td>Doses in Schedule</td>
<td>Interval Between Doses: Authorized</td>
<td>Interval Between Doses: Minimum</td>
<td>COVaxON: Agent Name</td>
<td>COVaxON: Trade Name</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------</td>
<td>----------------------</td>
<td>------------------------</td>
<td>-----------------</td>
<td>------------------</td>
<td>-----------------------------------</td>
<td>-------------------------------</td>
<td>---------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Sinopharm</td>
<td>May-7-2021</td>
<td>COVID-19 vaccine BIBP</td>
<td>Sinopharm COVID-19 Vaccine BIBP-CorV BBIBP – CorV Covilo</td>
<td>Inactivated virus</td>
<td>2</td>
<td>21-28 days</td>
<td>N/A</td>
<td>COVID-19 inactivated virus unspecified</td>
<td>SINOPHARM-BIBP COVID-19 Vaccine</td>
</tr>
<tr>
<td>Sinovac</td>
<td>Jun-1-2021</td>
<td>AdS-nCoV Sinovac CoronaVac</td>
<td>Sinovac COVID-19 Vaccine CoronaVac Sinovac CoronaVac PiCoVacc</td>
<td>Inactivated virus</td>
<td>2</td>
<td>14-28 days</td>
<td>N/A</td>
<td>COVID-19 inactivated virus unspecified</td>
<td>CoronaVac COVID-19 Vaccine</td>
</tr>
</tbody>
</table>

a The name of vaccine manufacturer who has applied for and received emergency use listing (EUL) from the World Health Organization (WHO).1
b The date the vaccine product obtained emergency use listing (EUL) from the World Health Organization (WHO).1
c The interval between doses in the vaccine series as authorized by the vaccine manufacturer.
d For COVID-19 vaccines authorized for use by Health Canada, refers to the minimum interval between doses in a vaccine series as recommended by Canada’s National Advisory Committee on Immunization (NACI).3
e Sinopharm (Beijing, BIBP-CorV) has been authorized by the WHO as an EUL vaccine, but Sinopharm (Wuhan, WIBP-CoV) has only been authorized for use in China. COVID-19 Vaccine (Vero cell) is being used on some COVID-19 immunizations records to refer to both Sinopharm and Sinovac.
* For a list of authorized vaccines by country, please see COVID 19 Vaccine Tracker: Trials & Approved Vaccines by Country5.
** Trade names vary by country/region; this list includes all currently known trade names.
*** For update to date information on vaccine efficacy and effectiveness, please see National Advisory Committee on Immunization (NACI) Recommendations on the Use of COVID-19 Vaccines3 and WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) COVID-19 Vaccine Technical Documenets.4
References


Citation

Disclaimer
This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario’s government, public health organizations and health care providers. PHO’s work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

Public Health Ontario
Public Health Ontario is an agency of the Government of Ontario dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit publichealthontario.ca.

©Queen’s Printer for Ontario, 2021